Phase 2 Data for Tisagenlecleucel, Tafasitamab Show Objective Responses in More Than Half of Patients

June 19, 2021 03:22pm

Both sets of data were unveiled at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which was held earlier this month in a virtual format.

Study Finds Genomics, Precision Medicine May Exacerbate Racial Disparities in Prostate Cancer
Analysis Supports Link Between AD, MDD Pathogenesis
Review Finds 3% of Patients With MS Have Epilepsy, 2% Experience Seizures
Study Details Effects of Hidradenitis Suppurativa on QOL